BERKELEY, Calif., June 8, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced the presentation of new preclinical results with XOMA 052 in the diet-induced obesity mouse model. XOMA 052 addresses the inflammatory cause of Type 2 diabetes by targeting interleukin 1 beta (IL-1 beta), a master signaling protein which triggers inflammatory pathways. The results were presented at the American Diabetes Association (ADA) 69th Scientific Sessions in New Orleans, Louisiana.
